Histology
Invasive Carcinoma
CI-CAN-00001040Explore in graph →
603 active trials9 approved drugs37 evidence items
- NCIt
- C9480
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001040Explore in graph →
Clinical trials
1,812 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (282)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06619236 | Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer(RAINFOL-02) | active not recruiting | Phase 3 | 584 | GenmabINDUSTRY | 18 | Sep 28, 2026 | clinicaltrials |
| NCT06211764 | A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)(SunRISe-5) | active not recruiting | Phase 3 | 272 | Janssen Research & Development, LLC |
| 14 |
| Sep 25, 2026 |
| clinicaltrials |
| NCT06205316 | SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma | active not recruiting | Phase 3 | 118 | Mayo ClinicOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05538663 | Intravesical BCG vs GEMDOCE in NMIBC(BRIDGE) | active not recruiting | Phase 3 | 870 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03070886 | Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery | active not recruiting | Phase 2 / Phase 3 | 612 | NRG OncologyOTHER | 3 | Sep 14, 2026 | clinicaltrials |
| NCT02750826 | Breast Cancer WEight Loss Study (BWEL Study) | active not recruiting | Phase 3 | 3,177 | Alliance for Clinical Trials in OncologyOTHER | 4 | Sep 2, 2026 | clinicaltrials |
| NCT02954874 | Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | active not recruiting | Phase 3 | 1,195 | National Cancer Institute (NCI)NIH | 3 | Aug 31, 2026 | clinicaltrials |
| NCT01081262 | Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer | active not recruiting | Phase 3 | 50 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT01272037 | Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer | active not recruiting | Phase 3 | 5,018 | National Cancer Institute (NCI)NIH | 10 | Aug 28, 2026 | clinicaltrials |
| NCT02839707 | Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 2 / Phase 3 | 444 | National Cancer Institute (NCI)NIH | 2 | Aug 28, 2026 | clinicaltrials |
| NCT03775265 | Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer | active not recruiting | Phase 3 | 475 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04878094 | A Study of Intra-operative Imaging in Women With Ovarian Cancer | active not recruiting | Phase 3 | 155 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04134260 | Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial | active not recruiting | Phase 3 | 586 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT04513717 | Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial | active not recruiting | Phase 3 | 2,753 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT05776758 | Role of NAC in cT0 Muscle-invasive Bladder Cancer After Maximal TURBt | active not recruiting | Phase 3 | 236 | Regina Elena Cancer InstituteOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06235151 | Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer(Solar-Stage) | active not recruiting | Phase 3 | 439 | Curium US LLCINDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT02446600 | Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 3 | 579 | National Cancer Institute (NCI)NIH | 4 | Jul 31, 2026 | clinicaltrials |
| NCT02445391 | Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | active not recruiting | Phase 3 | 415 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Jul 27, 2026 | clinicaltrials |
| NCT02502266 | Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer | active not recruiting | Phase 2 / Phase 3 | 582 | National Cancer Institute (NCI)NIH | 5 | Jul 1, 2026 | clinicaltrials |
| NCT04457596 | T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial | active not recruiting | Phase 3 | 1,056 | Alliance for Clinical Trials in OncologyOTHER | 3 | Jun 15, 2026 | clinicaltrials |
| NCT01953588 | Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | active not recruiting | Phase 3 | 1,473 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jun 5, 2026 | clinicaltrials |
| NCT01167712 | Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 692 | National Cancer Institute (NCI)NIH | 3 | May 29, 2026 | clinicaltrials |
| NCT04622319 | A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) | active not recruiting | Phase 3 | 1,600 | Daiichi SankyoINDUSTRY | 31 | May 15, 2026 | clinicaltrials |
| NCT04498117 | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery(FLORA-5) | active not recruiting | Phase 3 | 615 | CanariaBio Inc.INDUSTRY | 14 | Apr 1, 2026 | clinicaltrials |
| NCT04095364 | Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 3 | 450 | NRG OncologyOTHER | 6 | Mar 24, 2026 | clinicaltrials |
| NCT03842982 | Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)(CHIPPI) | active not recruiting | Phase 3 | 362 | Centre Oscar LambretOTHER | 2 | Mar 16, 2026 | clinicaltrials |
| NCT07109414 | Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) | active not recruiting | Phase 2 / Phase 3 | 380 | Novita Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT03414970 | Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer | active not recruiting | Phase 3 | 898 | Alliance for Clinical Trials in OncologyOTHER | 2 | Feb 24, 2026 | clinicaltrials |
| NCT05316181 | CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER)(KOV-HIPEC-02R) | active not recruiting | Phase 3 | 140 | National Cancer Center, KoreaOTHER_GOV | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04455750 | A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy(CASPAR) | active not recruiting | Phase 3 | 61 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03367702 | Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer | active not recruiting | Phase 3 | 692 | NRG OncologyOTHER | 6 | Jan 15, 2026 | clinicaltrials |
| NCT00565851 | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 1,052 | National Cancer Institute (NCI)NIH | 3 | Dec 30, 2025 | clinicaltrials |
| NCT04446117 | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC(CONTACT-02) | active not recruiting | Phase 3 | 575 | ExelixisINDUSTRY | 27 | Dec 18, 2025 | clinicaltrials |
| NCT04379570 | Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy | active not recruiting | Phase 3 | 1,167 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT01952223 | A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse(PEACE2) | active not recruiting | Phase 3 | 761 | UNICANCEROTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT03522246 | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy(ATHENA) | active not recruiting | Phase 3 | 1,097 | pharmaand GmbHINDUSTRY | 24 | Jun 24, 2025 | clinicaltrials |
| NCT02859038 | Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) | active not recruiting | Phase 3 | 489 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 2 | Feb 10, 2025 | clinicaltrials |
| NCT03949283 | Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer | active not recruiting | Phase 3 | 150 | Cordgenics, LLCINDUSTRY | 1 | Aug 22, 2024 | clinicaltrials |
| NCT03595592 | Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer(APTneo) | active not recruiting | Phase 3 | 650 | Fondazione MichelangeloOTHER | 4 | Mar 6, 2024 | clinicaltrials |
| NCT02221999 | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients(SHPD002) | active not recruiting | Phase 2 / Phase 3 | 250 | RenJi HospitalOTHER | 1 | Aug 29, 2023 | clinicaltrials |
Data updated 24 hours agoSource updated Sep 28, 2026source: clinicaltrials